What is the structural formula of pemetinib? Is it a targeted drug?

Pemigatinib is an oral, small-molecule tyrosine kinase inhibitor that selectively targets the fibroblast growth factor receptors (FGFR) 1, 2 and 3. Its structural formula is the chemical formula C24H30ClN7O2. It has a relatively complex organic small molecule structure, including a pyrrolopyrimidine core and multiple substituent groups, giving it the ability to bind FGFRkinase with high selectivity. Pemetinib achieves anti-tumor effects by inhibiting the FGFR signaling pathway and blocking the proliferation and angiogenesis of tumor cells.

As a targeted drug, pemetinib specifically targets tumors with FGFR gene mutations or fusions, especially in patients with cholangiocarcinoma and some bladder cancers. Abnormalities in the FGFR pathway drive tumor growth and metastasis in a variety of cancers. Pemetinib effectively blocks this signaling pathway by selectively inhibiting FGFR kinase activity, inhibiting the proliferation and survival of tumor cells, thereby achieving precise treatment.

Clinical studies have shown that pemetinib shows significant efficacy in the treatment of patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements, significantly extending the progression-free survival and overall survival rate of patients. Its advent fills an important gap in the field of FGFR targeted therapy and brings new treatment hope to patients with related cancers.

To sum up, pemetinib is a structurally complex and highly selective FGFR inhibitor, which belongs to the category of targeted drugs. It achieves the purpose of effectively controlling tumor growth by precisely inhibiting tumor-related signaling pathways, and has become an important drug choice in the treatment of related cancers.

Reference materials:https://www.drugs.com